
MSCLF
Healthcare · Biotechnology · $187.7M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2025 | Before the open | -0.04 | -0.03 | +13.0% |
| Aug 13, 2025 | Time not confirmed | — | -0.03 | — |
| May 13, 2025 | Time not confirmed | — | -0.05 | — |
| Mar 26, 2025 | Time not confirmed | — | -0.05 | — |
| Nov 13, 2024 | Before the open | -0.05 | -0.06 | -20.0% |
| Mar 30, 2023 | After the close | -0.05 | -0.05 | 0.0% |
| Nov 23, 2022 | After the close | -0.07 | -0.05 | +28.6% |
| Aug 29, 2022 | After the close | — | -0.05 | — |
| May 30, 2022 | After the close | — | -0.05 | — |
| Nov 29, 2021 | After the close | — | -0.34 | — |
| Aug 31, 2021 | After the close | — | -0.05 | — |
| Apr 29, 2021 | After the close | — | -0.08 | — |
| Nov 24, 2020 | After the close | — | -0.02 | — |
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company…
| May 15, 2020 |
| After the close |
| — |
| -0.06 |
| — |
| Nov 29, 2019 | After the close | — | -0.06 | — |
| Aug 28, 2019 | After the close | — | -0.05 | — |
| May 30, 2019 | After the close | — | -0.06 | — |
| Nov 29, 2018 | After the close | — | -0.08 | — |
| Aug 29, 2018 | After the close | — | -0.11 | — |
| May 30, 2018 | After the close | — | -0.08 | — |